Skip to main content
. 2007 Apr 3;91(10):1323–1326. doi: 10.1136/bjo.2006.113167

Table 2 Effect of multiple IVTA injections on visual acuity and central macular thickness over the course of the study.

1 injection, N = 6 2 injections, N = 8 3 injections, N = 13 4–5 injections, N = 6
Mean (SD) Δ Mean (SD) Δ Mean (SD) Δ Mean (SD) Δ p*
Visual acuity
Baseline 68.8 (6.4) 61.6 (14.8) 55.7 (12.8) 60.3 (6.8) 0.11
6.9 5.4 8.7 −3.0 0.05
6 months 75.7 (6.5) 67.0 (18.9) 64.4 (11.3) 57.3 (5.3) 0.31
−0.5 −0.5 −9.3 −3.1 0.25
12 months 75.2 (7.4) 66.5 (14.7) 55.1 (14.8) 54.2 (9.4) 0.10
−1.2 0.5 2.5 6.0 0.65
18 months 74.0 (6.4) 67.0 (16.2) 57.6 (10.3) 60.2 (11.8) 0.02
2.0 −7.0 1.3 5.5 0.15
24 months 76.0 (8.6) 60.0 (19.1) 58.9 (11.7) 65.7 (17.9) 0.12
p (trend)† 0.54 0.87 0.97 0.38
Final change 7.2 0.14 7.8 6.3 0.44
p‡ 0.02 0.98 0.006 0.47
Macular thickness
Baseline 405 (99) 407 (74) 503 (125) 381 (161) 0.36
168 126 157 2 0.82
6 months 237 (51) 281 (62) 346 (152) 379 (149) 0.23
−35 −40 −6 43 0.99
12 months 272 (135) 321 (104) 352 (71) 336 (147) 0.23
36 30 −8 63 0.70
18 months 236 (53) 291 (103) 360 (140) 293 (105) 0.31
−3 9 72 48 0.70
24 months 239 (57) 282 (126) 288 (98) 245 (43) 0.62
p (trend)† 0.01 0.06 0.002 0.12
Final change 148 92 172 88 0.84
p‡ 0.12 0.11 0.10 0.37

Data are grouped according to number of injections received during the study; Δ, change between consecutive 6‐month visits. *p value compares injection categories adjusting for duration of diabetes and HbA1C; †p value compares trend in visual acuity over 24 months; ‡p value compares baseline and 24‐month visit.